


Food and Drug Administration Rockville MD 20857

0346 5 APR 11 P2:07

Re: Daptacel Docket No. 03E-0251

The Honorable Jon Dudas
Under Secretary of Commerce for Intellectual Property and
Director of the United States Patent and Trademark Office
Box Pat. Ext.
P.O. Box 1450
Alexandria, VA 22313-1450



Dear Director Dudas:

This is in regard to the patent term extension application for U.S. Patent No. 5,667,787 filed by Aventis Pasteur under 35 U.S.C. § 156. The patent claims Daptacel (diptheria and tetanus toxoids and acellular pertussis vaccine adsorbed), BLA 103666/0.

In the July 7, 2004, issue of the <u>Federal Register</u> (69 Fed. Reg. 40945), the Food and Drug Administration published its determination of this product's regulatory review period, as required under 35 U.S.C. § 156(d)(2)(A). The notice provided that on or before January 3, 2005, 180 days after the publication of the determination, any interested person could file a petition with FDA under 35 U.S.C. § 156(d)(2)(B)(i) for a determination of whether the patent term extension applicant acted with due diligence during the regulatory review period.

The 180-day period for filing a due diligence petition pursuant to this notice has expired and FDA has received no such petition. Therefore, FDA considers the regulatory review period determination to be final.

Please let me know if we can provide further assistance.

Sincerely yours,

Jane A. Axelrad

Associate Director for Policy

Center for Drug Evaluation and Research

. alelus

cc: Patrick J. Halloran
Senior Patent Attorney - Director
Aventis Pasteur, Inc.
Discovery Drive

Swiftwater, PA 18370

03E-0251

LET 4